Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2023 08:00 ET | Source: AUM Biosciences Pte Ltd

AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer

SINGAPORE and BETHESDA, Md., May 30, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company focused on discovering and developing precision...
April 26, 2023 09:00 ET | Source: AUM Biosciences Pte Ltd

AUM Biosciences to Participate in Inaugural EF Hutton Global Conference

SINGAPORE and BETHESDA, Md., April 26, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company focused on advancing a pipeline of precision oncology...
January 05, 2023 08:00 ET | Source: AUM Biosciences Pte Ltd

AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma

SINGAPORE and BETHESDA, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotech company focused on discovering and developing precision oncology...
November 30, 2022 08:00 ET | Source: AUM Biosciences Pte Ltd

AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of Neuroblastoma

SINGAPORE and BETHESDA, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotech company focused on discovering and developing precision oncology...
November 15, 2022 08:00 ET | Source: AUM Biosciences Pte Ltd

AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia

SINGAPORE and BETHESDA, Md., Nov. 15, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical stage candidate and a broader pipeline...
November 04, 2022 08:30 ET | Source: AUM Biosciences Pte Ltd

AUM Biosciences to Participate in BioCentury-BayHelix East-West BioPharma Summit

SINGAPORE and BETHESDA, Md., Nov. 04, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical-stage pipeline of precision oncology...
October 20, 2022 05:00 ET | Source: AUM Biosciences Pte Ltd

AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V

The transaction reflects a pre-money equity value of $400 million for AUM BiosciencesTransaction is expected to provide $69 million of gross proceeds (assuming no redemptions by Mountain Crest...
August 18, 2022 08:00 ET | Source: AUM Biosciences Pte Ltd

AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTRK Fusion Gene

SINGAPORE and BETHESDA, Md., Aug. 18, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences, a global clinical-stage biotech company, focused on discovering and developing precision oncology therapeutics,...
June 07, 2022 08:00 ET | Source: AUM Biosciences Pte Ltd

AUM Biosciences Announces FDA IND Authorization for Global Phase 2 Trial of Selection Translation Inhibitor AUM001 in Colorectal Cancer

SINGAPORE and BETHESDA, Md., June 07, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences, a global clinical-stage biotech company, focused on discovering and developing precision oncology therapeutics, today...
May 17, 2022 08:00 ET | Source: AUM Biosciences Pte Ltd

AUM Biosciences Appoints an industry veteran, Scott Jordan as Head of Corporate Development

BETHESDA, Md., May 17, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences, a global clinical-stage biotech company focused on advancing a clinical pipeline of precision oncology therapeutics designed to...

Next Page keyboard_arrow_right